Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[In the primary marrow samples, methylation of TET2 occurred in two (5.9%) patients with essential thrombocythaemia (4.4% of all patients), both without JAK2 V617 mutation, but not in polycythaemia vera or primary myelofibrosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP884490.RAS9roRPfdLCS2tL03EcDrvDyaXoQfZHIiG6PXDX9_E6g130_assertion description "[In the primary marrow samples, methylation of TET2 occurred in two (5.9%) patients with essential thrombocythaemia (4.4% of all patients), both without JAK2 V617 mutation, but not in polycythaemia vera or primary myelofibrosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP884490.RAS9roRPfdLCS2tL03EcDrvDyaXoQfZHIiG6PXDX9_E6g130_provenance.
• NP659288.RAdeiU5JRQi4l922m5eWE1vjRiJiWLdcy64NSPbeCgkoU130_assertion description "[In the primary marrow samples, methylation of TET2 occurred in two (5.9%) patients with essential thrombocythaemia (4.4% of all patients), both without JAK2 V617 mutation, but not in polycythaemia vera or primary myelofibrosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP659288.RAdeiU5JRQi4l922m5eWE1vjRiJiWLdcy64NSPbeCgkoU130_provenance.
• NP519609.RA9gmj6kjIn9yxR0ZIe33U3y0346Aa4ivpXIcf4G6UrTc130_assertion description "[In the primary marrow samples, methylation of TET2 occurred in two (5.9%) patients with essential thrombocythaemia (4.4% of all patients), both without JAK2 V617 mutation, but not in polycythaemia vera or primary myelofibrosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP519609.RA9gmj6kjIn9yxR0ZIe33U3y0346Aa4ivpXIcf4G6UrTc130_provenance.
• NP914087.RAVeTptkMJNz_ke1nJNAuAFVnIUMQSvcRzqAA0kaSzXxY130_assertion description "[In the primary marrow samples, methylation of TET2 occurred in two (5.9%) patients with essential thrombocythaemia (4.4% of all patients), both without JAK2 V617 mutation, but not in polycythaemia vera or primary myelofibrosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP914087.RAVeTptkMJNz_ke1nJNAuAFVnIUMQSvcRzqAA0kaSzXxY130_provenance.
• assertion description "[In the primary marrow samples, methylation of TET2 occurred in two (5.9%) patients with essential thrombocythaemia (4.4% of all patients), both without JAK2 V617 mutation, but not in polycythaemia vera or primary myelofibrosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[In the primary marrow samples, methylation of TET2 occurred in two (5.9%) patients with essential thrombocythaemia (4.4% of all patients), both without JAK2 V617 mutation, but not in polycythaemia vera or primary myelofibrosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[In the primary marrow samples, methylation of TET2 occurred in two (5.9%) patients with essential thrombocythaemia (4.4% of all patients), both without JAK2 V617 mutation, but not in polycythaemia vera or primary myelofibrosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[In the primary marrow samples, methylation of TET2 occurred in two (5.9%) patients with essential thrombocythaemia (4.4% of all patients), both without JAK2 V617 mutation, but not in polycythaemia vera or primary myelofibrosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP829533.RAT2YpebxuJ5H228AQVNR0to1LRSq_ekA9H11kV82xROw130_assertion description "[In the primary marrow samples, methylation of TET2 occurred in two (5.9%) patients with essential thrombocythaemia (4.4% of all patients), both without JAK2 V617 mutation, but not in polycythaemia vera or primary myelofibrosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP829533.RAT2YpebxuJ5H228AQVNR0to1LRSq_ekA9H11kV82xROw130_provenance.
• NP914066.RAt92TAVORZF1MWkc7tQrGyq2w86opohAzSjaahSPfYHM130_assertion description "[In the primary marrow samples, methylation of TET2 occurred in two (5.9%) patients with essential thrombocythaemia (4.4% of all patients), both without JAK2 V617 mutation, but not in polycythaemia vera or primary myelofibrosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP914066.RAt92TAVORZF1MWkc7tQrGyq2w86opohAzSjaahSPfYHM130_provenance.
• NP829531.RAJ08W95EKkTAI7e64NSDtDnxMK9FxjsQo42rpxsvw3QM130_assertion description "[In the primary marrow samples, methylation of TET2 occurred in two (5.9%) patients with essential thrombocythaemia (4.4% of all patients), both without JAK2 V617 mutation, but not in polycythaemia vera or primary myelofibrosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP829531.RAJ08W95EKkTAI7e64NSDtDnxMK9FxjsQo42rpxsvw3QM130_provenance.
• NP913879.RA3xKg1BXOhjuKX4ih28It8vh-k_vX2PMyOLXhW7Ytcy0130_assertion description "[In the primary marrow samples, methylation of TET2 occurred in two (5.9%) patients with essential thrombocythaemia (4.4% of all patients), both without JAK2 V617 mutation, but not in polycythaemia vera or primary myelofibrosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP913879.RA3xKg1BXOhjuKX4ih28It8vh-k_vX2PMyOLXhW7Ytcy0130_provenance.
• NP829525.RAynNC3_6L4fyLasC8QwkMA8DfalazyGopa4lNhnmg9a4130_assertion description "[In the primary marrow samples, methylation of TET2 occurred in two (5.9%) patients with essential thrombocythaemia (4.4% of all patients), both without JAK2 V617 mutation, but not in polycythaemia vera or primary myelofibrosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP829525.RAynNC3_6L4fyLasC8QwkMA8DfalazyGopa4lNhnmg9a4130_provenance.
• NP829534.RA5vb5Y1KsgM27B0tlR9O-n8F5yj6V-svbXarV-6NWVWc130_assertion description "[In the primary marrow samples, methylation of TET2 occurred in two (5.9%) patients with essential thrombocythaemia (4.4% of all patients), both without JAK2 V617 mutation, but not in polycythaemia vera or primary myelofibrosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP829534.RA5vb5Y1KsgM27B0tlR9O-n8F5yj6V-svbXarV-6NWVWc130_provenance.